Literature DB >> 22785207

Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells.

Venkata Mahidhar Yenugonda1, Yali Kong, Tushar B Deb, Yonghong Yang, Rebecca B Riggins, Milton L Brown.   

Abstract

Resveratrol (RSV), a natural compound present in the skin and seeds of red grapes, is considered a phytoestrogen and has structural similarity to the synthetic estrogen diethylstilbestrol. RSV inhibits tumor cell growth in estrogen receptor-positive (ER+) and negative (ER-) breast cancer cell lines resulting in cell specific regulation of the G1/S and G2/M stages of the cell cycle. However apoptotic cell death was only observed in ER+ MCF-7 cells. In this study, we designed and synthesized boronic acid derivative of RSV and evaluated their biological effects on ER+ MCF-7 breast cancer cells. The trans-4 analog inhibited the growth of MCF-7 cells and is not a substrate for p-glycoprotein. The trans-4 analog induces G1 cell cycle arrest, which coincides with marked inhibition of G1 cell cycle proteins and a greater pro-apoptotic effect. Finally, the trans-4 analog had no effect on the estrogen-stimulated growth of MCF-7 cells. Our results demonstrate that the trans-4 analog inhibits MCF-7 breast cancer cells by a different mechanism of action than that of RSV (S-phase arrest), and provides a new class of novel boronic acids of RSV that inhibit breast cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785207      PMCID: PMC3679116          DOI: 10.4161/cbt.20845

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  45 in total

1.  Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation.

Authors:  Eun Yong Chung; Byung Hak Kim; Jin-Tae Hong; Chong-Kil Lee; Byeongwoo Ahn; Sang-Yoon Nam; Sang-Bae Han; Youngsoo Kim
Journal:  J Nutr Biochem       Date:  2010-12-28       Impact factor: 6.048

2.  Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase(,).

Authors:  S Ness; R Martin; A M Kindler; M Paetzel; M Gold; S E Jensen; J B Jones; N C Strynadka
Journal:  Biochemistry       Date:  2000-05-09       Impact factor: 3.162

3.  Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats.

Authors:  Elisabeth Wenzel; Tomislav Soldo; Helmut Erbersdobler; Veronika Somoza
Journal:  Mol Nutr Food Res       Date:  2005-05       Impact factor: 5.914

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.

Authors:  Anait S Levenson; Barry D Gehm; Sandra Timm Pearce; Jun Horiguchi; Laura A Simons; James E Ward; J Larry Jameson; V Craig Jordan
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

6.  Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.

Authors:  K P Bhat; D Lantvit; K Christov; R G Mehta; R C Moon; J M Pezzuto
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.

Authors:  L Altucci; R Addeo; L Cicatiello; S Dauvois; M G Parker; M Truss; M Beato; V Sica; F Bresciani; A Weisz
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

8.  3,5,3',4',5'-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells.

Authors:  Min-Hsiung Pan; Chih-Li Lin; Jie-Heng Tsai; Chi-Tang Ho; Wei-Jen Chen
Journal:  J Agric Food Chem       Date:  2010-01-13       Impact factor: 5.279

Review 9.  Current status of paclitaxel in the treatment of breast cancer.

Authors:  J A O'Shaughnessy; K H Cowan
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 10.  AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.

Authors:  Eliza Vakana; Leonidas C Platanias
Journal:  Oncotarget       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.